Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.
about
A comprehensive review on metabolic syndromeCardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateLipid-lowering agents in the management of nonalcoholic fatty liver diseaseLimitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.The metabolic syndromePrevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemiaThe effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis.Evidence-based management of carotid artery diseaseDyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentCombination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model.Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial.Are we getting to lipid targets in real life?Assessment of Carotid Artery Stenosis and the Use of Statins.Ezetimibe-Statin Combination Therapy.Stroke prevention: managing modifiable risk factors.Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs.The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.Human cholesterol metabolism and therapeutic molecules.Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.A new method for measurement of total plasma PCSK9: clinical applications.The impact of ezetimibe on endothelial function and other markers of cardiovascular risk.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Emerging options in the treatment of dyslipidemias: a bright future?Assessment of low-density lipoprotein targets.Second line options for hyperlipidemia management after cardiac transplantation.A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.Statins and their increased risk of inducing diabetes.The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.Pharmacological management of diabetic dyslipidemia.Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?Dietary phospholipids and intestinal cholesterol absorption.Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.Is there a problem with ezetimibe or just ENHANCEd hype?Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?Role of the apical and basolateral domains of the enterocyte in the regulation of cholesterol transport by a high glucose concentration.
P2860
Q21284500-BCB0290F-34AB-4676-A2F3-1ED0259ED85FQ26997059-88CF2CD3-B134-43E0-B034-097A676C869BQ27024352-B3BF2FD4-505D-4695-AEFF-E4EE07AB084BQ33559274-6607AC53-EB50-4C42-8999-1B5A1510BE2CQ33569142-09B56B8F-911A-4913-B0B8-6C0B9930029DQ33669805-7D07825B-8347-40F5-A6A5-2004055E30F2Q34113497-3D51E62A-5746-4C89-9CFC-979294ADA932Q34175306-F5015478-5B6A-4665-AB80-359245AAB9E0Q35029623-F0A08CC6-1679-4168-AC23-2D9B3306ECB8Q35125665-E5069CE3-F635-453A-97DD-EDC1F68933F7Q35203211-3051530F-EFD6-441C-987F-40CA0B4E8ABDQ35674362-0AF83BDC-14D9-4953-9BE5-81364CD07AFDQ35817670-5B27EE94-6A8C-45C3-A3AF-106AC28B500EQ36065333-2B0CFCB2-B3FE-4FB1-840B-F09B64DCD45DQ36076916-65EEC790-569E-44CF-83C3-92776317EACAQ36418118-C180304C-3485-4A80-9C57-B5B466C83573Q36729113-117A8F29-4EEE-4B68-9036-B559ECF95611Q36730488-A69FA2B0-3ECA-49FF-B2CB-FC68319E8218Q37000746-76A01D8B-51FA-4C66-897F-5B44948A885DQ37047547-E39B0B5F-7487-4A49-B020-8CEC968371A4Q37324420-7DA58F55-6AE5-4A1E-824B-0658F4480E2DQ37463260-0A05AFFD-927D-4305-8CB7-AFB4C4ED9864Q37634194-00E8CF32-FDBE-4DDC-92FF-CFEB71EB136EQ37772510-960BC358-DF55-4355-B943-5A7741DBC41FQ37827882-3CA66062-AAE9-450E-989B-94742D01A482Q37842462-1EFF2CB3-5815-47F0-A093-E1B28101E40AQ38021775-D65C6243-6C75-447C-BA7F-6A48D01DD792Q38041209-7554197E-DAC8-4B86-ACAF-3C515EC38151Q38113494-752D76C2-7FD0-46AF-80F6-5DA9311C69E0Q38599323-2990F17F-0F62-4B7C-87C2-A24D747E4349Q38742876-9382DA7B-965A-46DA-8204-5981AF8E55AFQ38828773-284B67B8-60C6-4E3B-B77D-982BE1EDE295Q39015072-EFC749D0-B01B-4B6E-B90C-63D7E0B8F510Q39515241-354940A6-FB96-4651-85A4-21BF814D9BDFQ40378508-1221D2EB-EE47-4C24-BF68-446642979F14Q41589413-6B07E632-1856-46AC-A9A0-AE415FB96416Q42698562-EA4180B5-6EB2-4A26-89C0-132F42ABC507Q43157168-55EDB9F9-A4A1-433C-88E3-FD255B6C3CEEQ46237709-2750498A-A276-4C32-8584-B0CE57FDE177Q46424797-C5FCE285-CD74-42B3-8F37-900784A11020
P2860
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Meta-analysis of the cholester ...... ded to ongoing statin therapy.
@en
type
label
Meta-analysis of the cholester ...... ded to ongoing statin therapy.
@en
prefLabel
Meta-analysis of the cholester ...... ded to ongoing statin therapy.
@en
P2093
P356
P1476
Meta-analysis of the cholester ...... ded to ongoing statin therapy.
@en
P2093
Ballantyne CM
Catapano AL
Mikhailidis DP
Sibbring GC
P304
P356
10.1185/030079907X210507
P407
P577
2007-08-01T00:00:00Z